Mindy I. Davis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mindy I. Davis has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Matthew B. Boxer
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA
3 shared publications- Anton Simeonov
National Institutes of Health
2 shared publications - Atsuo T. Sasaki
Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan; Division of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, United States; Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima 734-8551, Japan
2 shared publications - Kazutaka Sumita
Institute of Science Tokyo
2 shared publications - Koh Takeuchi
The University of Tokyo
2 shared publications - Matthew D. Hall
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
2 shared publications
Latest Publications
- 27 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 718, 149981
A high dose KRP203 induces cytoplasmic vacuoles associated with altered phosphoinositide segregation and endosome expansion
- 27 April 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 718, 149981
A high dose KRP203 induces cytoplasmic vacuoles associated with altered phosphoinositide segregation and endosome expansion
- Open Access
- 5 September 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (Supplement) , S337-S354
Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development
The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) Workshop on 3D Tissue Models for Antiviral Drug Development, held virtually on 7–8 June 2022, provided comprehensive coverage of critical concepts intended to help scientists establish robust, reproducible, and scalable 3D tissue models to study viruses with pandemic potential. This workshop was organized by NCATS, the National Institute of Allergy and Infectious Diseases, and the Bill and Melinda Gates Foundation. During the workshop, scientific experts from academia, industry, and government provided an overview of 3D tissue models’ utility and limitations, use of existing 3D tissue models for antiviral drug development, practical advice, best practices, and case studies about the application of available 3D tissue models to infectious disease modeling. This report includes a summary of each workshop session as well as a discussion of perspectives and challenges related to the use of 3D tissues in antiviral drug discovery.
- 5 September 2023
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (Supplement) , S337-S354
Open AccessReport of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development
The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) Workshop on 3D Tissue Models for Antiviral Drug Development, held virtually on 7–8 June 2022, provided comprehensive coverage of critical concepts intended to help scientists establish robust, reproducible, and scalable 3D tissue models to study viruses with pandemic potential. This workshop was organized by NCATS, the National Institute of Allergy and Infectious Diseases, and the Bill and Melinda Gates Foundation. During the workshop, scientific experts from academia, industry, and government provided an overview of 3D tissue models’ utility and limitations, use of existing 3D tissue models for antiviral drug development, practical advice, best practices, and case studies about the application of available 3D tissue models to infectious disease modeling. This report includes a summary of each workshop session as well as a discussion of perspectives and challenges related to the use of 3D tissues in antiviral drug discovery.
- Open Access
- 26 August 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 679, 116-121
Multimodal action of KRP203 on phosphoinositide kinases in vitro and in cells
- 26 August 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 679, 116-121
Open AccessMultimodal action of KRP203 on phosphoinositide kinases in vitro and in cells
- Open Access
- 1 October 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (10) , 6023-6033
Identification of Novel Plasmodium falciparum Hexokinase Inhibitors with Antiparasitic Activity
Plasmodium falciparum , the deadliest species of malaria parasites, is dependent on glycolysis for the generation of ATP during the pathogenic red blood cell stage. Hexokinase (HK) catalyzes the first step in glycolysis, transferring the γ-phosphoryl group of ATP to glucose to yield glucose-6-phosphate. Here, we describe the validation of a high-throughput assay for screening small-molecule collections to identify inhibitors of the P. falciparum HK (PfHK). The assay, which employed an ADP-Glo reporter system in a 1,536-well-plate format, was robust with a signal-to-background ratio of 3.4 ± 1.2, a coefficient of variation of 6.8% ± 2.9%, and a Z′-factor of 0.75 ± 0.08. Using this assay, we screened 57,654 molecules from multiple small-molecule collections. Confirmed hits were resolved into four clusters on the basis of structural relatedness. Multiple singleton hits were also identified. The most potent inhibitors had 50% inhibitory concentrations as low as ∼1 μM, and several were found to have low-micromolar 50% effective concentrations against asexual intraerythrocytic-stage P. falciparum parasites. These molecules additionally demonstrated limited toxicity against a panel of mammalian cells. The identification of PfHK inhibitors with antiparasitic activity using this validated screening assay is encouraging, as it justifies additional HTS campaigns with more structurally amenable libraries for the identification of potential leads for future therapeutic development.
- 1 October 2016
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (10) , 6023-6033
Open AccessIdentification of Novel Plasmodium falciparum Hexokinase Inhibitors with Antiparasitic Activity
Plasmodium falciparum , the deadliest species of malaria parasites, is dependent on glycolysis for the generation of ATP during the pathogenic red blood cell stage. Hexokinase (HK) catalyzes the first step in glycolysis, transferring the γ-phosphoryl group of ATP to glucose to yield glucose-6-phosphate. Here, we describe the validation of a high-throughput assay for screening small-molecule collections to identify inhibitors of the P. falciparum HK (PfHK). The assay, which employed an ADP-Glo reporter system in a 1,536-well-plate format, was robust with a signal-to-background ratio of 3.4 ± 1.2, a coefficient of variation of 6.8% ± 2.9%, and a Z′-factor of 0.75 ± 0.08. Using this assay, we screened 57,654 molecules from multiple small-molecule collections. Confirmed hits were resolved into four clusters on the basis of structural relatedness. Multiple singleton hits were also identified. The most potent inhibitors had 50% inhibitory concentrations as low as ∼1 μM, and several were found to have low-micromolar 50% effective concentrations against asexual intraerythrocytic-stage P. falciparum parasites. These molecules additionally demonstrated limited toxicity against a panel of mammalian cells. The identification of PfHK inhibitors with antiparasitic activity using this validated screening assay is encouraging, as it justifies additional HTS campaigns with more structurally amenable libraries for the identification of potential leads for future therapeutic development.